Journal article
Mass Oral Azithromycin for Childhood Mortality: Timing of Death After Distribution in the MORDOR Trial
Travis C Porco, John Hart, Ahmed M Arzika, Jerusha Weaver, Khumbo Kalua, Zakayo Mrango, Sun Y Cotter, Nicole E Stoller, Kieran S O'Brien, Dionna M Fry, Benjamin Vanderschelden, Catherine E Oldenburg, Sheila K West, Robin L Bailey, Jeremy D Keenan, Thomas M Lietman
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2019
DOI: 10.1093/cid/ciy973
Abstract
In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites. Here, we present a prespecified secondary analysis showing that much of the protective effect was in the first 3 months postdistribution. Distributing more frequently than biannually could be considered if logistically feasible. Clinical Trials Registration. NCT02047981.
Grants
Awarded by Bill & Melinda Gates Foundation
Funding Acknowledgements
The Bill & Melinda Gates Foundation provided the funding for the trial (grant number OP1032340). Pfizer Inc (New York City) provided both the azithromycin and the placebo oral suspensions. The Salesforce Foundation provided user licenses to Salesforce. com and cloud storage.